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Abstract
Background: There is preliminary evidence to suggest curcumin can alleviate digestive symptoms in adults with self-
reported digestive complaints and irritable bowel syndrome. However, in all these trials, curcumin was used as a
component of a multi-herbal combination and there were consistent concerns associated with risk of bias in most
studies. The goal of this study was to investigate the effects of a curcumin extract (Curcugen™) on gastrointestinal
symptoms, mood, and overall quality of life in adults presenting with self-reported digestive complaints. Moreover, to
determine the potential therapeutic mechanisms of action associated with curcumin, its effects on intestinal microbiota
and small intestinal bowel overgrowth (SIBO) were examined.
Methods: In this 8-week, parallel-group, double-blind, randomised controlled trial, 79 adults with self-reported
digestive complaints were recruited and randomised to receive either a placebo or 500 mg of the curcumin
extract, Curcugen™. Outcome measures included the Gastrointestinal Symptom Rating Scale (GSRS), intestinal
microbial profile (16S rRNA), Depression, Anxiety, and Stress Scale – 21 (DASS-21), Short Form-36 (SF-36), and SIBO
breath test.
Results: Based on self-report data collected from 77 participants, curcumin was associated with a significantly
greater reduction in the GSRS total score compared to the placebo. There was also a greater reduction in the
DASS-21 anxiety score. No other significant between-group changes in self-report data were identified. An
examination of changes in the intestinal microbial profile and SIBO test revealed curcumin had no significant
effect on these parameters. Curcumin was well-tolerated with no significant adverse events.
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Conclusions: The curcumin extract, Curcugen™, administered for 8 weeks at a dose of 500 mg once daily was
associated with greater improvements in digestive complaints and anxiety levels in adults with self-reported
digestive complaints. Compared to the placebo, there were no significant changes in intestinal microbiota or
SIBO; however, further research using larger samples and testing methods that allow more detailed microbial
analyses will be important. An investigation into other potential mechanisms associated with curcumin’s
gastrointestinal-relieving effects will also be important such as examining its influence on the intestinal barrier
function, inflammation, neurotransmitter activity, and visceral sensitivity.
Trial registration: Australian New Zealand Clinical Trials Registry, Trial ID. ACTRN12619001236189. Registered 6
September 2019.
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Background
Turmeric, the dried or fresh rhizome of the plant Cur-
cuma longa L., has been extensively used in traditional
medicine. In Ayurvedic medicine (a system of traditional
medicine originating from India), turmeric is believed to
have many medicinal properties including strengthening
the overall energy of the body, relieving gas, dispelling
worms, improving digestion, regulating menstruation, dis-
solving gallstones, and relieving arthritis. In many South
Asian countries, it is also used as an antiseptic for cuts,
burns, and bruises; and as an antibacterial agent [1].
Turmeric contains several phytochemicals such as tur-
merones and various polysaccharides, however, most of its
therapeutic activities are believed to result from a group of
yellow pigments known as curcuminoids. Curcuminoids
are a mixture of curcumin, demethoxycurcumin, bisdeme-
thoxycurcumin, and cyclocurcumin. Of these, curcumin is
the principal curcuminoid and has attracted the greatest
interest in the scientific literature [2]. Curcumin has been
shown to target multiple signalling molecules with most
of its benefits believed to be due to its antioxidant and
anti-inflammatory effects [3]. There is evidence to suggest
it may be beneficial for the treatment of pain and arthritis
[4, 5], metabolic syndrome [6], depression [7, 8], and cog-
nitive impairment [9]. Interest in the effects of curcumin
on digestive health is also accumulating and there is pre-
liminary evidence to suggest that it may be beneficial. In a
review by Lopresti [10], it was postulated that curcumin
may be helpful for the treatment of gastrointestinal (GI)
conditions because of its multiple effects on the GI system
including its influence on intestinal microbiota, intestinal
permeability, gut inflammation and oxidative stress; and
bacterial, parasitic, and fungal infections. In a meta-
analysis of 5 clinical trials on the use of curcumin for re-
ducing symptoms associated with irritable bowel syn-
drome (IBS), it was concluded that there was overall
evidence of efficacy [11]. However, in all these trials, cur-
cumin was used as a component of a multi-herbal com-
bination and there were consistent concerns associated
with risk of bias in most studies. Beneficial effects from
curcumin have also been identified in inflammatory bowel
diseases and functional gastrointestinal diseases (FGID)
[12–14].
The goal of this 8-week, randomised, double-blind,
placebo-controlled trial was to investigate the effects of a
curcumin extract (Curcugen™) on GI symptoms, mood,
and overall quality of life in adults presenting with self-
reported digestive complaints. In addition, to determine
the potential therapeutic mechanisms of action associ-
ated with curcumin, its effects on intestinal microbiota
and small intestinal bowel overgrowth (SIBO) were ex-
amined. In several animal trials [15–17] and one small
human trial [18], curcumin ingestion was associated with
changes in gut microbiota. For example, in an animal
trial, curcumin intake for 6 weeks resulted in increases
in the Firmicutes/ Bacteroidetes ratio compared to a ve-
hicle control [15], and in a human 8-week trial, turmeric
and curcumin supplementation was associated with a 7
and 69% increase in detected species respectively, over
time [18]. In another small trial comprising eight healthy
adults, the ingestion of curry with turmeric significantly
increased the area under the curve of breath hydrogen
and shortened small-bowel transit time compared with a
curry mixture without turmeric [19]. Despite this pre-
liminary evidence of the GI effects of curcumin, and its
potential to impact on intestinal microbiota, there has
been no trial specifically examining the GI effects of the
curcumin extract, Curcugen™. However, it was hypothe-
sised that based on previous research into turmeric and
other curcumin extracts, Curcugen™ may be associated
with improvements in digestive symptoms and such




This was a two-arm, parallel-group, 8-week, randomised,
double-blind, placebo-controlled trial (Fig. 1). The trial
protocol was prospectively registered with the Australian
New Zealand Clinical Trials Registry (Trial ID. ACTR
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N12619001236189) and approved by the Human Re-
search Ethics Committee at the National Institute of In-
tegrative Medicine (approval number 0056E_2019). To
estimate the required sample size (based on a single out-
come variable), an a priori power analysis was under-
taken. Based on a previously conducted placebo-
controlled study on adults with digestive disturbances
using a herbal combination containing turmeric [20], an
effect size of 0.6 was predicted. Assuming a type one
error rate (alpha) of 5% and a power of 80%, the number
of participants required per group to find an effect for
the total score on Gastrointestinal Symptom Rating
Scale (GSRS) was estimated as 36. After allowing for a
10% drop out rate, we aimed to recruit at least 40 partic-
ipants per group.
Recruitment and randomisation
Participants were recruited across Australia through social
media advertisements between September and December
2019. Interested participants were directed to a website
page that provided information about the study and a re-
quest to complete an online screening questionnaire. This
questionnaire assessed for current digestive symptoms,
history of medical and psychiatric disorders, medication
use, alcohol, nicotine and other drug use, herb and vita-
min intake, and pregnancy/breastfeeding status. If judged
as likely eligible, volunteers participated in a phone inter-
view with an investigator. The phone interview comprised
a series of questions to further obtain information relating
to the eligibility criteria and to acquire further demo-
graphic details. Suitable participants then completed on-
line versions of the Gastrointestinal Symptom Rating
Scale (GSRS), Depression, Anxiety, and Stress Scale
(DASS-21), Short-Form-36 (SF-36), and an informed con-
sent form. Using a randomisation calculator (http://www.
randomization.com), eligible and consenting participants
were randomly assigned to one of two groups (curcumin
or placebo). The randomisation structure comprised 10
randomly-permuted blocks, containing 8 participants per
block. Participant identification numbers were allocated
according to the order of participant enrolment in the
study. All capsules were packed in identical bottles la-
belled by two intervention codes (held by the study spon-
sor until final data analysis). Participants and study
Fig. 1 Systematic Illustration of Study Design
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investigators were blind to treatment group allocation
until all outcome data were collected and analysed. No fi-
nancial compensation was provided to participants for
participating in this study, although after the study, partic-
ipants allocated to the placebo condition were given a
complimentary 8-week supply of curcumin capsules.
Participants
Inclusion criteria
Male and female participants aged 18 to 65 years, with
self-reported symptoms of gastrointestinal complaints
were recruited for this study. Participants had a GSRS
average rating of between 2 (mild-severity gastrointes-
tinal discomfort) and 5 (moderately-severe gastrointes-
tinal discomfort). All participants were medication-free
for at least 4 weeks except for the use of the contracep-
tive pill and no more than once a week use of pain-
relieving medications. Volunteers had had no plan to
change their diet or commence new treatments over the
study period and had a body mass index (BMI) between
20 and 35. Participants were also fluent in English and
have consented (via an online consent form) to all per-
tinent aspects of the trial.
Exclusion criteria
Participants were ineligible to participate in the study if
they were diagnosed with a medical condition including,
but not limited to: diabetes, hyper/hypotension, cardio-
vascular disease, gallbladder disease/gallstones, biliary
disease, endocrine disease, psychiatric disorder, or
neurological disease (Parkinson’s, Alzheimer’s disease,
intracranial haemorrhage, head or brain injury). Partici-
pants diagnosed by a medical practitioner with a GI dis-
ease (e.g., inflammatory bowel diseases and FGID) were
also unable to participate in this study. Participants who
reported consuming greater than 14 standard alcoholic
drinks per week, a current or 12-month history of illicit
drug abuse, used antibiotics in the 4-weeks before study
commencement, were taking curcumin supplements, or
were currently taking supplements that may affect di-
gestive function (unless they were on a stable dose for
60 days before the baseline assessment) were also ineli-
gible for the study. Women who were pregnant, breast-
feeding, or intending to fall pregnant were also ineligible
to participate in the study.
Interventions
Placebo and curcumin capsules were matched for
colour, shape, and size. The active treatment, supplied
by DolCas Biotech, LLC., contained 500mg of a standar-
dised curcuminoids extract (Curcugen™). Curcugen™ is a
dispersible, 98.5% turmeric-based ingredient, containing
50% curcuminoids, 1.5% essential oils and other native
turmeric molecules. By increasing the surface area of the
curcuminoids, polar-resins facilitate the self-dispersion
of otherwise lipophilic curcuminoids for greater access
to absorptive surfaces and extended plasma retention.
The placebo capsules contained the same excipients as
the active tablet (microcrystalline cellulose). All capsules
were manufactured and packed in a Good Manufactur-
ing Practice facility. All participants were instructed to
take one capsule daily with 250 ml of water immediately
before sleep for 8 weeks. Medication adherence was
monitored by asking participants to count remaining
capsules at weeks 4 and 8. The effectiveness of partici-
pant treatment blinding was assessed by asking partici-
pants to predict group allocation (placebo, curcumin, or
uncertain) at the completion of the study. Curcumin and
placebo capsules were mailed to participants with direc-
tions for use provided on capsule bottles. An informa-
tion sheet was also provided to participants with details
about how to take the capsules. This information was




Gastrointestinal symptom rating scale (GSRS) total
score The GSRS is a self-report, 15-item questionnaire
that measures the severity of a wide range of gastrointes-
tinal symptoms. Questions are rated on a 7-point scale
ranging from no discomfort at all (1) to very severe dis-
comfort (7). A total score is calculated by averaging the
ratings provided on all questions. The GSRS has good
psychometric properties and in several clinical trials has
shown to be sensitive to treatment effects [21, 22]. The
GSRS was completed at baseline, week 4, and week 8.
Microbial profile At baseline and week 8, participants
collected a stool sample at home after a morning bowel
motion. Participants were instructed to collect approxi-
mately 1 g of stool into a collection tube (Zymo DNA/
RNA Shield faecal collection tube) and return samples
via express post to our office for later analysis. DNA/
RNA Shield reagent is a DNA and RNA stabilisation so-
lution for nucleic acids that preserves the genetic integ-
rity and expression profiles of samples at ambient
temperatures and completely inactivates infectious
agents. The DNA and RNA stabilisation solution also
prevents degradation from freeze-thaw cycling and
unexpected freezer failures. Samples were stored in a −
20-degree Celsius freezer until later analysis. Intestinal
microbiota via 16S rRNA (V3-V4 region) gene sequen-
cing was undertaken by Australian Genome Research
Facility. Paired-ends reads were assembled by aligning
the forward and reverse reads using PEAR (version
0.9.5). Primers were identified and trimmed. Trimmed
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sequences were processed using Quantitative Insights
into Microbial Ecology (QIIME 1.8.4) USEARCH (ver-
sion 8.0.1623) and UPARSE software. Using USEARCH
tools, sequences were quality filtered, full length dupli-
cate sequences were removed and, were sorted by abun-
dance. Singletons or unique reads in the data set were
discarded. Sequences were clustered followed by chimera
filtered using “rdp_gold” database as a reference. To ob-
tain the number of reads in each operational taxonomic
unit (OU) U, reads were mapped back to OTUs with a
minimum identity of 97%. Taxonomy was assigned using
QIIME. OTU changes in intestinal bacteria at the
phylum and family level and changes in microbial diver-
sity (Shannon and Simpson diversity index) from base-
line to week 8 were examined.
Secondary outcome measures
Gastrointestinal symptom rating scale (GSRS) cluster
scores In addition to a GSRS total score, five symptom clus-
ters can also be calculated comprising scores for reflux, ab-
dominal pain, indigestion, diarrhoea, and constipation.
Depression, anxiety, and stress scale – 21 (DASS-21)
The DASS-21 is a validated self-report measure asses-
sing symptoms of stress, anxiety, and depression [23].
Twenty one questions are rated on a 4-point scale (0–3),
ranging from never to almost always (lower scores indi-
cate a reduction in symptoms). Sub-scale scores for de-
pression, anxiety, and stress are calculated. The DASS-
21 was completed at baseline, week 4, and week 8.
Short Form-36 health survey (SF-36) The SF-36 is a
self-report measure assessing quality of life. Scores are cal-
culated for eight areas including (1) energy/fatigue, (2)
physical functioning, (3) bodily pain, (4) general health
perceptions, (5) physical role functioning, (6) emotional
role functioning, (7) social role functioning, and (8) emo-
tional wellbeing. The SF-36 is a commonly-used outcome
measure of quality of life with strong psychometric prop-
erties [24, 25]. Scoring for the SF-36 was based on the al-
gorithm developed by RAND Health Care [26]. The SF-36
was completed at baseline, week 4, and week 8.
Small intestinal bacterial overgrowth (SIBO) A 3-h
SIBO home breath test was conducted at baseline and
week 8. After a 24-h preparatory diet, a lactulose sub-
strate was ingested, and breath samples were collected
every 20 min for 3 h. Tests using the QuinTron Breath-
Tracker were used to measure levels of carbon dioxide
(CO2), hydrogen, and methane in a single sample of
breath (alveolar air). CO2 levels below 1.5% were consid-
ered invalid breath collections. Positive, borderline, and
negative SIBO results were calculated based on the fol-
lowing criteria:
 Elevated hydrogen results: Increases of hydrogen
greater than 20 ppm (ppm) over the lowest
preceding value within the first 100 min were
classified as positive results, and increases occurring
100–120 min later were classified as borderline.
 Elevated methane results: Increases of methane
greater than 12 ppm over the lowest preceding value
within the first 100 min were classified as positive
results, and increases occurring 100–120 min later
were classified as borderline.
 Elevated combined results: Increases of combined
hydrogen and methane gas values greater than 15
ppm over the lowest preceding value within the first
100 min were classified as positive results, and
increases occurring 100–120 min later were
classified as borderline.
Adverse events Safety and tolerability of supplement in-
take by participants were examined at weeks 4 and 8
through an online question querying adverse effects that
were believed to be associated with supplement intake.
Participants were also requested to contact researchers
immediately if any adverse effects were experienced.
Statistical analysis
An independent samples T-test was used to compare
demographic variables across the two treatment groups
for continuous variables, and Pearson’s Chi-square was
used to compare categorical data. To evaluate self-report
outcome measures, a repeated-measures analysis of vari-
ance (ANOVA) was used to compare within-group
changes over time (weeks 0, 4, and 8) and group (curcu-
min versus placebo) x time interaction effects. A Cohen’s
d was also calculated to examine effect sizes. The
Shapiro-Wilk normality test was conducted to examine
the normality of group data. This demonstrated that
data were not normally distributed, and this was not cor-
rected by data transformations. However, a repeated-
measures ANOVA was considered the most appropriate
option for statistical analyses as it is relatively robust to
violations of normality [27]. Where necessary, degrees of
freedom were adjusted using the Greenhouse-Geisser
approach to correct for violations of the sphericity as-
sumption. Data from participants were included in ana-
lyses of self-report outcomes if questionnaire data were
obtained at week 4 [last observation carried forward
from week 4 for missing values].
To examine SIBO results, a Mann-Whitney U-Test
was conducted to examine categorical differences (ele-
vated, borderline, and negative) for hydrogen, methane,
and combined gases between the two groups (curcumin
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and placebo) at the two time points (baseline and week
8). A Wilcoxon signed ranks test was also conducted to
evaluate within-group changes in SIBO results over time
(baseline and week 8) for the two groups (curcumin and
placebo).
Changes in intestinal bacteria were analysed using a
permutational multivariate analysis of variance (PERM
ANOVA) to evaluate the difference between pre- and
post-measures, by group (placebo vs curcumin), at the
phylum level. A simple t-test on the Simpson and Shan-
non diversity index to compare the change in bacterial
diversity by group at the phylum to genus levels was also
conducted. Moreover, a principal component analysis
(PCA) was completed to explore the relationship be-
tween samples.
A further exploratory analysis was conducted to exam-
ine changes in selected individual bacteria over time.
Based on the results of several systematic reviews exam-
ining differences in gut microbiota between adults with
irritable bowel syndrome and healthy adults, the follow-
ing gut microbiota was chosen for further exploratory
analysis: Bacteroidetes (Phyla), Firmicutes (Phyla), Clos-
tridia (class), Enterobacteriaceae (family), Bacteroides
(genus), Clostridiales (genus), Faecalibacterium (genus),
and Bifidobacterium (genus) [28–30]. Moreover, an ex-
ploratory analysis was conducted to examine the rela-
tionship between change in diversity index and change
in GSRS total score. Based on available data from both
groups, a Pearson’s correlation coefficient was calculated
at the phylum to genus levels. All data were analysed
using SPSS (version 26; IBM, Armonk, NY) and R (ver-




Baseline questionnaire and demographic information
From 175 people who completed the initial online
screening questionnaire, 79 volunteers met the eligibility
criteria and agreed to participate in the study. Self-
report data from 77 participants who completed at least
week-4 questionnaires were used for statistical analyses
of self-report outcome measures. Two participants, one
from each group, failed to consume the minimum num-
ber of required tablets (i.e., consumed less than 80% of
tablets). However, data from these participants were in-
cluded in the statistical analyses as removal of their re-
sults did not significantly influence statistical outcomes.
SIBO results were collected from 78 participants at base-
line and 69 participants at week 8. A basal hydrogen
value of more than 16 ppm is suggestive of non-
adherence to the preparatory diet [31]. This occurred in
1 participant at baseline and 9 participants at week 8.
However, all collected data were analysed as removal of
scores from these participants did not significantly affect
statistical results. Stool samples were collected by 71
participants at baseline and 58 participants at week 8.
However, valid pre and post stool samples were only
available for 50 participants (25 from each group). This
was because only one stool sample (either pre or post)
was collected/returned by the participant, or an inad-
equate sample was collected. Statistical analyses of
between-group changes were conducted on stool results
where both pre and post collections were conducted.
Baseline data for participants are detailed in Table 1.
There were no statistically-significant, between-group
differences in baseline outcome measures except for the
SF-36 pain score, where participants in the curcumin
group reported a lower pain score (indicating a higher
pain disability). A total of 9 participants withdrew from
the study and there were no significant differences in
dropout rates between the groups. Reasons for with-
drawal included no reason given (n = 4), the commence-
ment of antibiotics (n = 3), excess work commitments
(n = 1), and unrelated health issues (n = 1). No partici-
pants withdrew from the study due to reported adverse
events associated with capsule intake.
Outcome measures
GSRS total score (primary outcome measure)
Changes in GSRS total score across the two treatment
groups and repeated measures ANOVA significance
levels are detailed in Table 2 and Fig. 2. Reductions in
the GSRS total score from baseline to week 8, indicating
an improvement in symptoms, were significantly greater
in the curcumin group than the placebo group (F2,150 =
3.96, p = .021, ES = .57). Curcumin (F2,74 = 36.74,
p < .001) and placebo (F2,76 = 25.06, p < .001) administra-
tion was associated with statistically-significant reduc-
tions in the GSRS total score over time. Within-group
analyses revealed that the majority of the changes in the
GSRS total score occurred in the first 4 weeks of treat-
ment as there were statistically-significant reductions in
the GSRS total score from baseline to week 4 for both
the curcumin (F1,37 = 37.08, p < .001) and placebo
(F1,38 = 45.39, p < .001) groups. However, between-group
contrasts revealed a significant group x time interaction
from week 4 to week 8 for GSRS total score (F1, 75 =
6.433, p = .013). From weeks 4 to 8, there was a non-
significant decrease in GSRS total score in the curcumin
group (F1,37 = 2.92, p = .096) and a non-significant in-
crease in GSRS total score in the placebo group (F1,38 =
3.56, p = .067).
Microbial profile (primary outcome measure 2)
Based on the results of the PERMANOVA, there was a
non-significant between-group interaction in changes in
intestinal bacteria at the phylum level between the
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Table 1 Baseline demographic and outcome measures of participants
Placebo Curcumin p-value
n = 40 n = 39
Age
Mean 43.20 40.69 .325 a
SE 1.74 1.84
BMI
Mean 24.80 25.53 .404 a
SE 0.62 0.61
Gender (n)
Male 6 (15%) 4 (10%) .869b
Female 34 (85%) 35 (90%)
Marital Status (n)
Single 10 (25%) 15 (91%) .198 b
Married 30 (75%) 24 (38%)
Educational Level (n)
Secondary 16 (27%) 22 (56%) .137 b
Tertiary 15 (63%) 14 (36%)
Post-graduate 9 (10%) 8 (12%)
Exercise Level (n)
Never/Rarely 7 (18%) 5 (13%) .947 b
1 to 2 times a week 8 (20%) 8 (21%)
3 to 5 times a week 15 (37%) 38 (8%)
6+ times a week 10 (25%) 28 (18%)
Duration of gastrointestinal problems (n)
< 6 months 2 (5%) 1 (3%) .148 a
6 to 12 months 1 (10%) 0 (0%)
1–2 years 2 (2%) 4 (10%)
2 to 5 years 3 (8%) 9 (23%)
5 to 10 years 14 (35%) 6 (15%)
10+ years 18 (45%) 18 (46%)
GSRS: Total score
Mean 2.63 2.89 .106 a
SE 0.10 0.12
GSRS: Abdominal pain
Mean 2.50 2.5 .998 a
SE 0.14 0.13
GSRS: Reflux
Mean 2.06 2.14 .764 a
SE 0.18 0.19
GSRS: Diarrhoea
Mean 2.71 2.65 .872 a
SE 0.24 0.24
GSRS: Indigestion
Mean 3.15 3.52 .118 a
SE 0.15 0.18
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Table 1 Baseline demographic and outcome measures of participants (Continued)
Placebo Curcumin p-value
GSRS: Constipation
Mean 2.44 3.06 .059 a
SE 0.20 0.26
DASS-21: Total score
Mean 22.35 23.23 .830 a
SE 2.7 3.08
DASS-21: Depression
Mean 6.15 5.74 .798 a
SE 1.02 1.21
DASS-21: Anxiety
Mean 5.00 5.64 .598 a
SE 0.83 0.88
DASS-21: Stress
Mean 11.2 11.85 .730 a
SE 1.22 1.41
SF-36: Physical functioning
Mean 88.38 88.67 .605 a
SE 2.27 2.39
SF-36: Role limitations due to physical health
Mean 70.63 70.51 .990 a
SE 6.26 6.55
SF-36: Role limitations due to emotional problems
Mean 60.8 69.28 .306 a
SE 5.97 5.67
SF-36: Energy/fatigue
Mean 42.38 43.85 .748 a
SE 3.5 2.92
SF-36: Emotional wellbeing
Mean 68.4 73.23 .169 a
SE 2.38 2.54
SF-36: Social functioning
Mean 75.5 73.9 .750 a
SE 3.83 3.2
SF-36: General health
Mean 59.25 65.26 .206 a
SE 3.77 2.79
SF-36: Pain
Mean 74.55 63.36 .017 a
SE 2.95 3.47
SIBO n = 39 n = 39
Elevated hydrogen (n)
Negative 12 (31%) 13 (39%) .115 b
Borderline 7 (18%) 4 (12%)
Positive 20 (51%) 16 (48%)
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placebo and curcumin groups (F1,48 = 1.730, p = .169).
The visual inspection of the PCA (Fig. 3) also revealed
that there was no systematic movement in phyla concen-
trations in the baseline and week 8 samples.
The results of independent samples t-tests examining
changes in microbial diversity (Shannon and Simpson
index) over time between the two groups revealed there
were no statistically-significant between-group differences
in changes in the Shannon and Simpson index at the
phylum, class, order, or family level (see supplementary
Table 1). However, at the genus level, there was a
statistically-significant difference between the curcumin
and placebo groups for the Shannon (p = .020) and Simp-
son index (p = 0.06). This was characterised by a decrease
in the Shannon [T(24) = − 2.20, p = .038] diversity index in
the curcumin group. However, as there were baseline
Table 1 Baseline demographic and outcome measures of participants (Continued)
Placebo Curcumin p-value
Elevated methane (n)
Negative 16 (41%) 18 (46%) .446 b
Borderline 5 (13%) 8 (21%)
Positive 18 (46%) 13 (33%)
Elevated combined (n)
Negative 3 (8%) 8 (21%) .256 b
Borderline 8 (21%) 6 (15%)
Positive 28 (72%) 25 (64%)
a = Independent samples t-test; b = Chi-square Test





Repeated Measures ANOVA Cohen’s
D effect
size
p-value time effects p-value time x group interaction
GSRS: Total score Placebo (n = 39) Mean 2.65 2.00 2.18 <.001 .021 .57
SE 0.10 0.10 0.12
Curcumin (n = 38) Mean 2.91 2.24 2.10 <.001
SE 0.12 0.12 0.12
GSRS: Abdominal pain Placebo (n = 39) Mean 2.52 1.85 2.10 <.001 .124 .14
SE 0.14 0.12 0.15
Curcumin (n = 38) Mean 2.52 2.12 1.97 .001
SE 0.13 0.12 0.15
GSRS: Reflux Placebo (n = 39) Mean 2.04 1.81 1.88 .350 .638 .20
SE 0.18 0.17 0.20
Curcumin (n = 38) Mean 2.17 1.76 1.83 .021
SE 0.20 0.15 0.18
GSRS: Diarrhoea Placebo (n = 39) Mean 2.75 2.00 2.31 <.001 .314 .24
SE 0.24 0.16 0.21
Curcumin (n = 38) Mean 2.70 2.01 1.93 <.001
SE 0.24 0.18 0.18
GSRS: Indigestion Placebo (n = 39) Mean 3.18 2.22 2.46 <.001 .114 .41
SE 0.15 0.14 0.16
Curcumin (n = 38) Mean 3.53 2.52 2.39 <.001
SE 0.18 0.17 0.17
GSRS: Constipation Placebo (n = 39) Mean 2.43 1.98 1.97 .009 .160 .40
SE 0.20 0.14 0.16
Curcumin (n = 38) Mean 3.10 2.54 2.20 <.001
SE 0.26 0.22 0.20
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differences in diversity between the two groups, a univari-
ate analysis of variance was conducted with baseline diver-
sity scores included as a covariate. This revealed that
between-group differences in changes in diversity scores
were no longer significantly different for the Shannon
(F2,47 = 3.69, p = .061) and Simpson diversity (F2,47 = 1.92,
p = .171) index.
T-tests were conducted to examine OTU changes in
selected individual bacteria from the phylum to species
level. As detailed in supplementary Table 1 there were
no statistically-significant, between-group differences in
changes in the selected intestinal bacteria over time.
An exploratory analysis was conducted to examine the
relationship between change in the Shannon and Simp-
son diversity index and change in GSRS total score (sup-
plementary Table 2). Based on the Pearson’s correlation
coefficient, there was no significant relationship between
change in diversity index at any microbial level and GI
symptomatic improvements as measured by the GSRS
total score.
GSRS subscale scores (secondary outcome measure 1)
Changes in GSRS cluster scores for the two treatment
groups and repeated measures ANOVA significance levels
are detailed in Table 2. Concerning changes in all GSRS
cluster scores (abdominal pain, reflux, diarrhoea, indiges-
tion, and constipation) across the 8-week intervention,
there were no statistically-significant, between-group dif-
ferences. However, in the curcumin group there were
statistically-significant reductions in all GSRS cluster
scores comprising abdominal pain (F2,74 = 7.15, p = .001),
reflux (F2,74 = 4.04, p = .021), diarrhoea (F2,74 = 8.90,
Fig. 2 Change in GSRS Scores (error bars depict standard error)
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p < .001), indigestion (F2,74 = 28.88, p < .001), and constipa-
tion (F2,74 = 14.69, p < .001). In the placebo group, there
were statistically-significant reductions in GSRS cluster
scores for abdominal pain (F2,76 = 13.59, p < .001), diar-
rhoea (F2,76 = 8.42, p < .001), indigestion (F2,76 = 23.08,
p < .001), and constipation (F2,76 = 5.06, p = .009), but not
reflux (F2,76 = 1.06, p = .350).
DASS-21 (secondary outcome measure 2)
Changes in the DASS-21 scores for the two treatment
groups and repeated measures ANOVA significance levels
are detailed in Table 3. Reductions in the DASS-21 total
(F2,150 = 3.19, p = .044, ES = .46) and anxiety scores
(F2,150 = 3.85, p = .023, ES = .53) were significantly greater
in the curcumin group than the placebo group. However,
there were no between-group differences for changes in
the DASS-21 depression (F2,150 = 1.02, p = .363, ES = .26)
or stress (F2,150 = 1.87, p = .157, ES = .35) scores. In the
curcumin group, there were statistically-significant reduc-
tions in all DASS-21 scores; total (F2,74 = 14.25, p < .001),
depression (F2,74 = 5.58, p = .006), anxiety (F2,74 = 10.81,
p < .001), and stress (F2,74 = 9.93, p < .001) scores com-
pared to baseline levels. In the placebo group, there was a
statistically-significant reduction in the DASS-21 stress
score (F2,76 = 5.29, p = .007), but not the total (F2,76 = 2.96,
p = .058), anxiety (F2,76 = .995, p = .375), or depression
(F2,76 = .869, p = .423) scores compared to baseline levels.
SF-36 subscale scores (secondary outcome measure 3)
Changes in SF-36 scores for the two treatment groups
and repeated measures ANOVA significance levels are
detailed in Table 3. Improvements in the SF-36 pain
score (F2,150 = 3.85, p = .023, ES = .43) were greater in the
curcumin group than the placebo group. However, as
pain scores were significantly different at baseline be-
tween the two groups, a univariate analysis of variance
with baseline pain scores included as a covariate was
conducted. This revealed that between-group differences
in changes in pain scores were no longer significantly
different (F2,74 = 0.175, p = .677). For all other SF-36 sub-
scale scores, there were no statistically-significant,
between-group differences.
SIBO (secondary outcome measure 4)
SIBO tests results are detailed in Table 4. A basal hydro-
gen value of more than 16 ppm is suggestive of non-
adherence to the preparatory diet [31]. This occurred in
1 participant at baseline and 9 participants at week 8.
However, all collected data were included in analyses as
removal of data from these participants did not signifi-
cantly affect statistical outcomes. Based on the Mann-
Whitney U-Test, there were no statistically-significant,
between-group differences in the percentage of partici-
pants scoring in the elevated, borderline, or negative cat-
egories for either hydrogen, methane, or combined gases
Fig. 3 Principal Components Analysis (PCA) of Changes in Bacterial Concentrations (Phyla) for the Curcumin and Placebo Groups Over Time
(Time A = baseline; Time B = week 8)
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p-value time x group
interaction
DASS-21: Total Score Placebo (n =
39)
Mean 22.87 19.71 19.28 .058 .044 .46
SE 2.71 2.69 3.03
Curcumin
(n = 38)
Mean 23.42 13.95 13.89 <.001
SE 3.16 1.81 1.86
DASS-21: Depression Placebo (n =
39)
Mean 6.31 5.33 5.44 .423 .363 .26
SE 1.03 1.00 1.15
Curcumin
(n = 38)
Mean 5.79 3.42 3.47 .006
SE 1.25 0.72 0.64
DASS-21: Anxiety Placebo (n =
39)
Mean 5.08 4.67 4.26 .375 .023 .53
SE 0.85 0.86 0.83
Curcumin
(n = 38)
Mean 5.68 3.05 2.74 <.001
SE 0.90 0.57 0.59
DASS-21: Stress Placebo (n =
39)
Mean 11.49 9.18 9.59 .007 .157 .35
SE 1.22 1.16 1.30
Curcumin
(n = 38)
Mean 11.95 7.47 7.68 <.001
SE 1.45 0.82 0.95
SF-36: Physical functioning Placebo (n =
39)
Mean 88.08 89.74 91.92 .170 .250 .11
SE 2.31 2.77 2.60
Curcumin
(n = 38)
Mean 86.58 90.92 89.08 .019
SE 2.45 1.70 2.32




Mean 69.87 80.13 84.87 .137 .814 .03
SE 6.37 5.60 4.77
Curcumin
(n = 38)
Mean 69.74 84.87 81.41 .008
SE 6.68 2.32 5.09




Mean 59.79 66.67 77.79 .019 .476 .14
SE 6.03 6.13 5.53
Curcumin
(n = 38)
Mean 70.24 81.61 82.45 .060
SE 5.74 4.82 5.00
SF-36: Energy/fatigue Placebo (n =
39)
Mean 41.79 46.92 52.05 .003 .073 .11
SE 3.55 3.26 3.59
Curcumin
(n = 38)
Mean 44.47 56.58 52.63 <.001
SE 2.93 2.80 3.48
SF-36: Emotional wellbeing Placebo (n =
39)
Mean 67.90 71.69 79.47 .016 .272 .20
SE 2.39 2.93 2.06
Curcumin
(n = 38)
Mean 73.47 79.47 74.26 .047
SE 2.59 2.06 2.58
SF-36: Social functioning Placebo (n =
39)
Mean 74.87 85.13 89.92 <.001 .983 .01
SE 3.88 3.00 2.81
Curcumin
(n = 38)
Mean 74.18 85.05 88.97 <.001
SE 3.27 3.50 2.60
SF-36: General health Placebo (n =
39)
Mean 58.72 63.59 65.26 .002 .919 .08
SE 3.83 3.33 3.38
Lopresti et al. BMC Complementary Medicine and Therapies           (2021) 21:40 Page 12 of 17
at either baseline or week 8. A Wilcoxon signed ranks
test was conducted to examine changes in SIBO results
from baseline to week 8. There were no statistically-
significant changes in SIBO from baseline to week 8 in
the placebo group for either hydrogen (z = −.502, p =
.616), methane (z = −.427, p = .670) or combined gases
(z = −.884, p = .377); or the curcumin group for hydrogen
(z = − 1.539, p = .124), methane (z = − 1.734, p = .083) or
combined gases (z = −.262, p = .794).
Intake of supplements
At week 8, participants recorded their quantity of
remaining capsules. Two participants reported taking
less than 80% of their capsules over the 8 weeks, al-
though the consistency of use over the 8 weeks could
not be ascertained.
Adverse events
No significant adverse events were reported by partici-
pants and no participant withdrew from the study due
to concerns associated with supplement intake. The fre-
quency of adverse effects is detailed in supplementary
Table 3. These were no significant differences in re-
ported adverse effects between the two groups [placebo
(11) and curcumin (6)] and reported adverse effects were
of mild severity.
Efficacy of participant blinding
To evaluate the efficacy of condition concealment over
the study, participants were asked at the completion of
the study to predict condition allocation (i.e. placebo,
curcumin, or uncertain). Efficacy of group concealment
was high as only 31% in the curcumin group and 29% in
the placebo group correctly guessed treatment
allocation.
Discussion
In this 8-week, randomised, double-blind, placebo-
controlled trial, the administration of a curcumin extract
(Curcugen™) at a dose of 500 mg a day was associated














Mean 65.13 69.47 70.53 .031
SE 2.86 2.77 3.13
SF-36 - Pain Placebo (n =
39)
Mean 74.41 79.15 81.51 .018 .023 .43
SE 3.06 2.82 2.54
Curcumin
(n = 38)
Mean 62.66 77.61 77.29 <.001
SE 3.49 2.78 2.99
Table 4 Changes in SIBO results over time

















Elevated 51% 36% 15% .069 50% 46% 4% .447 .616 .124
Borderline
18% 10% 8% 21% 11% 9%
Negative 31% 54% −23% 29% 43% −13%
Methane
Elevated 46% 33% 13% .395 44% 54% −10% .247 .670 .083
Borderline
13% 21% −8% 15% 14% 0%
Negative 41% 46% −5% 41% 31% 10%
Combined
Elevated 72% 64% 8% .323 79% 74% 5% .420 .377 .794
Borderline
21% 15% 5% 15% 3% 12%
Negative 8% 21% −13% 6% 23% −17%
* Mann-Whitney U-Test (between-group differences as time points); # Wilcoxon signed ranks test (within-group changes in SIBO results from baseline to week 8)
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with a greater improvement in overall GI symptoms in
adults presenting with self-reported digestive complaints
compared to the placebo. After 8 weeks of treatment,
there was an average 28% reduction in overall digestive
symptoms in the curcumin group compared to 18% in
the placebo group. Moreover, from weeks 4 to 8, Curcu-
gen™ was associated with improvements in GI symp-
toms, while the placebo group experienced a worsening
in symptoms. In relation to symptomatic improvements,
curcumin was also associated with significant reductions
in abdominal pain, reflux, diarrhoea, indigestion, and
constipation; however, improvements were not signifi-
cantly different to those observed in the placebo group.
Improvements in quality of life and mood were also ob-
served after curcumin administration; however, except
for a greater reduction in anxiety, changes were not sig-
nificantly different from the placebo group. In adults
supplemented with curcumin, there was a 52% reduction
in anxiety symptoms compared to a 16% reduction in
the placebo group. These results suggest curcumin ad-
ministration was associated with improvements in over-
all GI symptoms and reductions in anxiety. Curcumin
was well-tolerated with no significant differences in ad-
verse effects between the curcumin and placebo groups.
To examine the potential mechanisms associated with
curcumin’s influence on the GI system, changes in intes-
tinal microbiota and SIBO were examined over the 8-
week intervention. Compared to the placebo, there were
no significant changes in microbial diversity (from the
phylum to genus level) or in examined selected micro-
biota comprising Bacteroidetes (Phyla), Firmicutes
(Phyla), Clostridia (class), Enterobacteriaceae (family),
Bacteroides (genus), Clostridiales (genus), Faecalibacter-
ium (genus), and Bifidobacterium (genus). These intes-
tinal bacteria were chosen for examination as differences
in these bacteria have been regularly observed in adults
with IBS [28–30]. An examination of the effects of cur-
cumin on SIBO also revealed curcumin did not influence
SIBO rates. These results suggest that although curcu-
min was associated with improvements in GI symptoms
(and anxiety levels) in adults with self-reported digestive
complaints, changes in intestinal bacteria were not re-
sponsible for its therapeutic mechanisms of action. Im-
portantly, despite increasing interest in the relationship
between microbial diversity and GI conditions, in this
study, increases in microbial diversity (from the phylum
to genus level) were not associated with GI symptomatic
improvements. This finding provides further confirm-
ation that in this examined population of adults with
self-reported digestive complaints, therapeutic actions of
curcumin were not via its impact on intestinal bacteria.
However, it is important to note that 16S rRNA analysis
was utilised in this study which lacks the resolution to
identify microbial changes at lower taxonomic
classifications (e.g., species and strain levels). Other po-
tential mechanisms associated with curcumin’s GI-
supporting effects include its influence on intestinal bar-
rier function, inflammation, neurotransmitter activity,
and visceral sensitivity; mechanisms which have been
identified as compromised in adults with GI distur-
bances. In a review by Ghosh et al. [32], it was demon-
strated that curcumin decreases the translocation of gut
bacteria-derived lipopolysaccharide (LPS) from the intes-
tinal lumen into circulation by maintaining the integrity
of the intestinal barrier. In particular, curcumin may
modulate intestinal barrier function at several layers in-
cluding the lumen (via its effect on intestinal alkaline
phosphatase), the mucus layer, the epithelium (through
its influence on the expression of tight junction pro-
teins), and antibacterial peptides (via its expression of
anti-microbial peptides). In an acute study, curcumin
supplementation reduced gastrointestinal damage and
associated pro-inflammatory cytokine activity in adults
exposed to exercise and heat stress [33]. Moreover, cur-
cumin has anti-inflammatory effects and this presents as
another mechanism associated with its therapeutic ef-
fects. Increased concentrations of systemic LPS are iden-
tified in several intestinal and extra-intestinal diseases
[34–37]. Curcumin has been identified in animal studies
to attenuate LPS-induced immune response and tissue
damage [38–40]. Disturbances in the activity of the
hypothalamus-pituitary-adrenal (HPA) axis have also
been identified in people with IBS and FGID [41–43].
Curcumin has been shown in animal studies to influence
HPA activity, and in human trials, is associated with
lower concentrations of cortisol [44, 45]. Disturbances in
serotonergic activity have also been implicated in GI dis-
eases and altered serotonergic signalling may lead to
both intestinal and extraintestinal symptoms in IBS [46].
This presents as another mechanism of action associated
with curcumin as it has been shown to influence seroto-
nergic activity [47, 48].
Limitations and directions for future research
Even though there were improvements in GI symptoms
in adults with self-reported GI complaints, these results
should be cautiously generalised to adults presenting
with diagnosed GI disorders until confirmation in future
clinical trials. How the severity of digestive complaints
in the population recruited in this study compares to
healthy individuals without GI complaints, or people
with diagnosed GI disorders, could not be evaluated as
there are no published norms for the GSRS. However, in
a study on 516 adults with gastroesophageal reflux dis-
ease, an average GSRS total score of 2.27 was identified
[21]. This suggests that the population of recruited par-
ticipants had a mild-to-moderate severity of GI symp-
toms, as their baseline GSRS score was 2.78 (a higher
Lopresti et al. BMC Complementary Medicine and Therapies           (2021) 21:40 Page 14 of 17
scores indicates increasing severity of symptoms). Fur-
ther examination of changes in GI symptoms utilising
other outcome measures will be helpful in future trials
to provide further analysis of symptomatic changes. Ex-
amples include the Bristol Stool Scale [49], clinician-
administered questionnaires, measures of colonic transit
time and stool frequency, and provocation tests for the
evaluation of visceral sensitivity [50, 51].
In this study, curcumin was administered as a once-
daily dose delivering 500 mg of a patented curcumin ex-
tract (Curcugen™). This equates to 250 mg of curcumi-
noids daily. Research confirms that there are significant
differences in the bioavailability and composition of cur-
cumin extracts. Curcugen™ is derived from a turmeric
oleoresin base with a 50% curcuminoid concentration.
In an unpublished study, it was associated with a 39-fold
increase in free curcumin compared to standard curcu-
min. Given the differences in the profile and bioavailabil-
ity of curcumin extracts, the GI effects of curcumin
should be cautiously extended to other curcumin ex-
tracts until further confirmatory research is conducted.
In future trials, the efficacy of curcumin should be ex-
amined using different doses, frequency of dosing, and
treatment duration. This will help to identify optimal
treatment regimens for people with GI disorders. Even
though no significant changes in intestinal microbiota
were identified in this study, different dosages and treat-
ment periods may lead to microbial changes. Moreover,
microbial changes may occur in adults with clearly de-
fined and diagnosed GI disorders including IBS, other
FGIDs, and inflammatory bowel disease. In this study,
adults with self-reported GI complaints with no previous
diagnosis of a GI disorder were recruited. In addition,
more detailed analysis of microbial changes at different
taxonomic levels (e.g., species or strain level) may have
revealed changes over time. However, for this greater
resolution to occur accurately, whole-genome testing is
preferred [52]. Other factors that may have affected the
lack of change in intestinal microbiota over time in-
cluded the recruitment of people taking the contracep-
tive pill, the inclusion of volunteers with a BMI in the
overweight and obese range, and limitations associated
with our ability to monitor or control for dietary
changes over time. The recruitment of larger samples
sizes may also be required to elucidate microbial
changes associated with curcumin use. Despite recruit-
ing 79 volunteers, pre- and post-treatment changes in
intestinal microbiota were only undertaken on 50 partic-
ipants but data on GSRS changes were available for 77
participants. This has the potential to confound the re-
sults. As already discussed, despite Curcugen™ supple-
mentation being associated with improvements in GI
symptoms and reductions in anxiety, its therapeutic
mechanisms of action could not be established. It will be
important in future trials to examine other potential
mechanisms of action of curcumin including examining
its effects on intestinal barrier function, inflammation,
HPA-axis activity, and serotonergic activity.
The results of this randomised, double-blind, placebo-
controlled study demonstrated that the 8-week adminis-
tration of a curcumin extract, Curcugen™ (500 mg daily),
was associated with significant improvements in GI
symptoms in adults presenting with self-reported digest-
ive complaints. Compared to the placebo, there were
also greater reductions in anxiety. Curcumin was well-
tolerated with no reported significant adverse effects. An
examination of the potential mechanisms associated with
curcumin supplementation suggests its therapeutic ef-
fects may not be due to its influence on intestinal micro-
biota. However, before definitive conclusions about the
effects of curcumin on intestinal bacteria can be made,
further research using larger sample sizes and testing
methods that allow more detailed analysis of microbial
changes at lower taxonomic levels (e.g., whole-genome
testing) will be important. Further studies on adults with
clearly-defined GI disorders, using objective and subject-
ive outcome measures, varying dosages and treatment
durations, and differing curcumin extracts are required
to elucidate the effects of curcumin on GI symptoms.
Further trials are also required to examine the potential
therapeutic actions of curcumin.
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